Onc.AI Company Research Report

Company Overview

• Name: Onc.AI

• Mission: Onc.AI is on a mission to radically improve oncology decision-making by developing a precision oncology care management platform that transforms clinical decision-making.

• Founded By: Akshay Nanduri and Salmaan Ahmed.

• Key People:

• Akshay Nanduri - Founder & CEO

• Salmaan Ahmed - Founder & VP Software

• Lester Boeh - Chief Operating Officer

• Rita Ciaravino - Chief Software Architect & VP AI/ML

• Petr Jordan, PhD - Chief Technology Officer

• Kevin Masukawa - Chief Commercial Officer

• Advisory Board:

• Jonathan Fleming - Chairman of Board

• Various prominent board members and advisors in the medical and scientific fields (detailed list above).

• Headquarters:

• San Carlos, California, USA

• Waterloo, Ontario, Canada

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Known for leveraging a market-leading oncology real-world dataset to develop AI models that improve oncology decision-making, with a focus on metastatic lung cancer patients treated using PD-1 immunotherapy.

Products

• Products Offered: Onc.AI is developing a pipeline of AI models intended to support medical oncologists in making treatment decisions.

• High-Level Description: The company's initial product is intended to aid oncologists by utilizing AI to evaluate data such as diagnostic imaging, EMR, labs, and genomics to assist in treatment decision-making for immune checkpoint inhibitors.

• Key Features:

• The AI-powered platform integrates multi-modal machine learning models.

• It utilizes radiomics to predict patient responses to PD-(L)1 immunotherapy.

• Focused on providing non-invasive tools for clinical decision-making.

Recent Developments

• Recent Developments:

• Onc.AI has secured significant financial funding rounds, including a $25 million Series A financing and a $6 million seed financing round, to support the commercialization of its clinical management solution and accelerate product development.

• New Products Launched: No explicitly stated new product launches.

• New Features Added:

• They have developed a radiomic survival prediction model designed for classifying patients based on treatment response likelihood.

• Improved radiomic assessment techniques that enhance prediction capabilities for immune checkpoint inhibitors.

• New Partnerships:

• Collaboration with Pfizer to evaluate the ability of Onc.AI’s radiomics-based multimodal signature in predicting immunotherapy response.

• Series A financing co-led by MassMutual and Action Potential Venture Capital, enhancing their financial capability to drive product commercialization.

Additional Information

• Events and Presentations:

• Onc.AI has been active in participating and presenting at major oncology and medical conferences, such as the American Society Of Clinical Oncology (ASCO) and American Medical Informatics Association (AMIA).

• Investor & Partner Info: The company has received investments from reputable firms including MassMutual, Action Potential Venture Capital, Blue Venture Fund, and prominent individual investors.

• Press Inquiries: Contact via press@onc.ai

This report summarizes the data available about Onc.AI, emphasizing their focus on leveraging AI for improving cancer treatment outcomes and supporting oncologists' clinical decision-making processes.